|Security||MGCD / MGC Diagnostics Corp. (552768103)|
|Institutional Shares||2,099 - 0.05%|
|Common Shares Outstanding||4,387,643 shares (as of 2016-10-31)|
Institutional Stock Ownership and Shareholders
MGC Diagnostics Corp. (NASDAQ:MGCD) has 1 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,099 shares.
Largest shareholders include
Renaissance Technologies LLC.
MGC Diagnostics Corp. (NASDAQ:MGCD) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|Fondren Management LP||97,090||0||-100.00||871||0||-100.00|
|BANK OF AMERICA CORP /DE/||14||0||-100.00||0||0|
|SPRINGBOK CAPITAL MANAGEMENT, LLC||4,214||0||-100.00||46||0||-100.00|
|Radoff Bradley Louis||341,199||0||-100.00|
|JAMES INVESTMENT RESEARCH INC||1,091||0||-100.00||12||0||-100.00|
|ACADIAN ASSET MANAGEMENT LLC||2,658||0||-100.00||24||0||-100.00|
|PERRITT CAPITAL MANAGEMENT INC||70,000||0||-100.00||628||0||-100.00|
|LADENBURG THALMANN FINANCIAL SERVICES INC||26||0||-100.00||0||0|
|ROYAL BANK OF CANADA||557||0||-100.00||6||0||-100.00|
|NORTHERN TRUST CORP||11,470||0||-100.00||126||0||-100.00|
|K2 PRINCIPAL FUND, L.P.||52,416||0||-100.00||578||0||-100.00|
|Brandywine Global Investment Management, LLC||44,200||0||-100.00||488||0||-100.00|
|CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM||16,310||0||-100.00||146||0||-100.00|
|DEUTSCHE BANK AG\||2,344||0||-100.00||21||0||-100.00|
|UBS Group AG||2,418||0||-100.00||27||0||-100.00|
|Renaissance Technologies LLC||267,040||2,099||-99.21|
|Advisory Services Network, LLC||1,625||0||-100.00||18||0||-100.00|
|KENNEDY CAPITAL MANAGEMENT, INC.||229,782||0||-100.00||2,534||0||-100.00|
|PERCEPTIVE ADVISORS LLC||329,733||0||-100.00|
|VANGUARD GROUP INC||80,771||0||-100.00||724||0||-100.00|
|GAMCO INVESTORS, INC. ET AL||372,255||0||-100.00|
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET
Financial Charts by Fintel.io
|Industry||Surgical and Medical Instruments and Apparatus|